New life for ARYx's tecarfarin as US FDA approves development plans
This article was originally published in Scrip
Executive Summary
The US FDA has told ARYx Therapeutics that its existing development pathway is acceptable and will enable a filing of its vitamin K antagonising anticoagulant tecarfarin.